Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE: 002693)
Health Care · Pharmaceuticals · CN
CN¥9.41
-5.33% today · +15.0% 1Y
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE: 002693) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $580.48M and employs 474 people.
Over the last twelve months the share price has gained 15.0%, trading between 6.36 and 12.43.
Tweenvest scores Hainan Shuangcheng Pharmaceuticals Co., Ltd. across four factors: quality 57/100, value 31/100, growth 0/100. Its strongest factor is quality.
002693 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $580.48M
- Revenue (TTM)
- $45.61M
- P/E
- 70.01
- EPS
- 0.13
- Dividend yield
- —
- Beta (5Y)
- 0.48
- 52-week high
- CN¥12.43
- 52-week low
- CN¥6.36
- Avg volume (3M)
- —
- Shares outstanding
- 414.69M
- Employees
- 474
- Next earnings
- —
About Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Hainan Shuangcheng Pharmaceuticals Co., Ltd. operates internationally, undertaking the entire lifecycle of synthetic peptide drugs and active pharmaceutical ingredients (APIs), from initial research and development through manufacturing to global market distribution. Its extensive product portfolio encompasses a wide array of injectable medications, including somatostatin, thymosin, clindamycin hydrochloride, thymopentin, L-carnitine, uranin hydrobromide, inosine, cyclophosphine adenosine, motidine, scopolamine, and sodium ferulate. Additionally, the company provides vitamin B6. Founded in 2000, the firm is headquartered in Haikou, People's Republic of China.
- ISIN
- CNE100001K63
- Founded
- 2000
- Listed since
- Aug 8, 2012
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.